"Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update"
Since initial US Food and Drug Administration approval of botulinum toxin type A (BoNT-A) for aesthetic use in 2002, clinical evidence and experience with BoNT-A and understanding of facial anatomy have greatly increased, leading to rapid advances in treatment plan-ning and implementation.
BoNT-A use has expanded from the upper face to the midface, lower face, and neck, so that BoNT-A injection is the most common cosmetic procedure worldwide. Trends in facial aesthetics reflect growing patient diversity with respect to age, gender, and ethnicity. In October 2019, a multidisciplinary panel of 6 experts in minimally invasive injectable procedures in the special-ties of dermatology and plastic surgery convened at the 2019 American Society for Dermatologic Surgery (ASDS) meeting in Chicago, IL. Their goal was to discuss recent advances in BoNT-A use in facial aesthetics, including implications of the introduction of new agents in light of an evolving patient population.
To receive a CME certificate of participation, you should:
• Read the entire publication, including the CME information.
• Register or log in at www.paradigmmc.com/822 to complete and submit the online posttest and evaluation.
Following online completion of the posttest and evaluation, a certificate of participation will be available for download/printing immediately.